| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -22,969 | -20,555 | -23,342 | -34,640 |
| Stock-based compensation expense | 1,916 | 1,429 | 1,582 | 3,277 |
| Depreciation expense | 49 | 49 | 50 | 134 |
| Net amortization of premiums and discounts on investments | 346 | 692 | 50 | 624 |
| Amortization of debt discount | - | 0 | 0 | 0 |
| Other | -84 | -13 | -47 | 289 |
| Prepaid expenses and other current assets | 1,947 | -297 | -2,656 | 2,319 |
| Decrease in other assets | - | 0 | 0 | 0 |
| Decrease in operating lease liabilities | - | -416 | -407 | -783 |
| Decrease in operating lease right-of-use asset | - | -275 | -267 | -509 |
| Decrease in other long-term liabilities | - | 0 | 0 | 0 |
| Accounts payable | -1,868 | -564 | -1,276 | -509 |
| Accrued expenses | -346 | 4,243 | 4,923 | 2,224 |
| Operating right-of-use assets and operating lease liabilities, net | 144 | - | - | - |
| Net cash used in operating activities | -25,571 | -15,921 | -15,550 | -33,020 |
| Purchases of property and equipment | 6 | 7 | - | - |
| Purchases of investments | 10,726 | 90,022 | 17,841 | 55,228 |
| Proceeds from sales and maturities of investments | 33,187 | 32,884 | 37,479 | 91,094 |
| Net cash provided by investing activities | 22,455 | -57,145 | 19,638 | 35,866 |
| Proceeds from issuance of common stock and pre-funded warrants, net | - | 74,575 | 2,851 | 0 |
| Repayment of short-term borrowings | - | 0 | 0 | 0 |
| Repayment of long-term borrowings | - | 0 | 0 | 0 |
| Net cash provided by (used in) financing activities | - | 74,575 | 2,851 | 0 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -3,116 | 1,509 | 6,939 | 2,846 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 29,162 | 27,653 | 17,868 | - |
| Cash, cash equivalents, and restricted cash at end of the period | 26,046 | 29,162 | 27,653 | - |
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)